Quarterly report pursuant to Section 13 or 15(d)

Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details)

v3.23.1
Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 20,620,408 5,125,167
Lucid Diagnostics In 2018 Equity Plan Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 5,052,458 2,864,427
Lucid Diagnostics In 2018 Equity Plan Unvested Restricted Stock Awards [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 1,872,100 2,260,740
Lucid Diagnostics In 2018 Equity Plan Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 13,695,850